Clinical Trial Update: Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of ME3183 in adults with moderate to severe plaque psoriasis; results have been posted (June 2024).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ME3183

Snippet

Sponsor: Meiji Pharma USA Inc. | Conditions: Plaque Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2024-06-27